The latest price target for Crinetics Pharmaceuticals (NASDAQ:CRNX) was reported by Citizens on March 2, 2026. The analyst firm set a price target for $96.00 expecting CRNX to rise to within 12 months (a possible 156.07% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) was provided by Citizens, and Crinetics Pharmaceuticals maintained their market outperform rating.

The last upgrade for Crinetics Pharmaceuticals Inc happened on January 12, 2026 when Goldman Sachs raised their price target to $67. Goldman Sachs previously had a neutral for Crinetics Pharmaceuticals Inc.

There is no last downgrade for Crinetics Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crinetics Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crinetics Pharmaceuticals was filed on March 2, 2026 so you should expect the next rating to be made available sometime around March 2, 2027.

While ratings are subjective and will change, the latest Crinetics Pharmaceuticals (CRNX) rating was a maintained with a price target of $105.00 to $96.00. The current price Crinetics Pharmaceuticals (CRNX) is trading at is $37.49, which is out of the analyst’s predicted range.